Abstract
Background: Worldwide S. aureus are increasingly displaying resistance to multiple drug classes. Therapeutic options to multi-drug resistant (MDR) S. aureus phenotypes are limited. Tigecycline, a new glycylcycline offers the potential of enhanced activity against MDR S. aureus. The tigecycline evaluation surveillance trial (T.E.S.T.) evaluated the activity of tigecycline and comparators to MDR S. aureus isolated worldwide. Methods: 335 hospital sites in 47 countries between 2004 and 2007 collected 7,557 clinically significant S. aureus. MICs were determined using broth microdilution panels and results interpreted as specified by CLSI at each site. S. aureus strains were categorized into groups according to the number of drug classes to which they were resistant (MDR groups 0 to 4). Results: MIC90 of tigecycline and comparators for MDR groups 0 to 4 are shown in the table. Conclusions: Tigecycline in comparison to 10 relevant comparators exhibited the lowest MIC90 against S. aureus isolated worldwide irrespective of MDR phenotype and multiple drug class resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
